Mendelian randomization: Methods for using genetic variants in causal estimation

Mendelian Randomization: Methods for Using Genetic Variants in Causal Estimation

Volumn , Issue , 2015, Pages 1-207

  Burgess, Stephen ^a   Thompson, Simon G ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054240713     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b18084     Document Type: Book

References (249)

1. Allin, K., Nordestgaard, B., Zacho, J., Tybjærg-Hansen, A., and Bojesen, S. 2010. C-reactive protein and the risk of cancer: a Mendelian randomization study. Journal of the National Cancer Institute, 102(3):202–206. (Cited on page 11.)
2. Almon, R., Álvarez-Leon, E., Engfeldt, P., Serra-Majem, L., Magnuson, A., and Nilsson, T. 2010. Associations between lactase persistence and the metabolic syndrome in a cross-sectional study in the Canary Islands. European Journal of Nutrition, 49(3):141–146. (Cited on page 11.)
3. Anderson, T. and Rubin, H. 1949. Estimators of the parameters of a single equation in a complete set of stochastic equations. Annals of Mathematical Statistics, 21(1):570–582. (Cited on pages 54 and 108.)
4. Angrist, J., Graddy, K., and Imbens, G. 2000. The interpretation of instrumentalvariablesestimatorsinsimultaneousequationsmodelswithanapplication to the demand for fish. Review of Economic Studies, 67(3):499–527. (Cited on pages 48, 56, and 177.)
5. Angrist, J., Imbens, G., and Rubin, D. 1996. Identification ofcausal effects using instrumental variables. Journal of the American Statistical Association, 91(434):444–455. (Cited on pages 38, 41, and 176.)
6. Angrist, J. and Krueger, A. 1992. The effect of age at school entry on educational attainment: An application of instrumental variables with moments from two samples. Journal of the American Statistical Association, 87(418):328–336. (Cited on page 146.)
7. Angrist, J. and Pischke, J. 2009. Mostly harmless econometrics: an empiricist’s companion. Chapter 4: Instrumental variables in action: sometimes you get what you need. Princeton University Press. (Cited on pages 56, 57, 58, 61, 67, and 108.)
8. Basmann, R. 1960. Onfinite sample distributions of generalized classicallinear identifiability test statistics. Journal of the American Statistical Association, 55(292):650–659. (Cited on page 68.)
9. Baum, C., Schaffer, M., and Stillman, S. 2003. Instrumental variables and GMM:Estimationandtesting. Stata Journal, 3(1):1–31. (Citedonpages67, 68, and 69.)
10. Baum, C., Schaffer, M., and Stillman, S. 2007. Enhanced routines for instrumental variables/generalized method of moments estimation and testing. Stata Journal, 7(4):465–506. (Cited on page 67.)
11. Bech, B., Autrup, H., Nohr, E., Henriksen, T., and Olsen, J. 2006. Stillbirth and slow metabolizers of caffeine: comparison by genotypes. International Journal of Epidemiology, 35(4):948–953. (Cited on page 11.)
12. Beer, N., Tribble, N., McCulloch, L., et al. 2009. The P446Lvariant in GCKR associated with fasting plasma glucoseand trigly ceride levels exertsits effect through increased glucokinase activity in liver. Human Molecular Genetics, 18(21):4081–4088. (Cited on page 95.)
13. Bekker, P. 1994. Alternative approximations to the distribution so finstrumental variable estimators. Econometrica: Journal of the Econometric Society, 62(3):657–681. (Cited on pages 61 and 108.)
14. Beral, V., Banks, E., Bull D., Reeves, G. (Million Women Study Collaborators) 2003. Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet, 362(9382):419–427. (Cited on page 4.)
15. Bochud, M., Chiolero, A., Elston, R., and Paccaud, F. 2008. Acautionarynote on the use of Mendelian randomization to infer causation in observational epidemiology. International Journal of Epidemiology, 37(2):414–416. (Cited on page 32.)
16. Bochud, M. and Rousson, V. 2010. Usefulness of Mendelian randomization in observational epidemiology. International Journal of Environmental Research and Public Health, 7(3):711–728. (Cited on page 9.)
17. Borenstein, M., Hedges, L., Higgins, J., and Rothstein, H. 2009. Introduction to meta-analysis. Chapter 34: Generality of the basic inverse-variance method. Wiley. (Cited on page 140.)
18. Bound, J., Jaeger, D., and Baker, R. 1995. Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak. Journal of the American Statistical Association, 90(430):443–450. (Cited on pages 99 and 104.)
19. Bowden, J. and Vansteelandt, S. 2011. Mendelian randomisation analysis of case-control data using structural mean models. Statistics in Medicine, 30(6):678–694. (Cited on pages 51 and 159.)
20. Brennan, P., McKay, J., Moore, L., et al. 2009. Obesity and cancer:Mendelian randomization approachutilizing the FTO genotype. International Journal of Epidemiology, 38(4):971–975. (Cited on page 89.)
21. Brion, M.-J., Shakhbazov, K., and Visscher, P. 2013. Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 42(5):1497–1501. (Cited on page 128.)
22. Browning, S. 2006. Multilocus association mapping using variable-length Markov chains. American Journal of Human Genetics, 78(6):903–913. (Cited on page 134.)
23. Browning, S. and Browning, B. 2007. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. American Journal of Human Genetics, 81(5):1084–1097. (Cited on page 134.)
24. Buonaccorsi, J. 2005. Encyclopedia of Biostatistics, chapter Fieller’s theorem, pages 1951–1952. Wiley. (Cited on page 53.)
25. Burgess, S. 2012a. Statistical issues in Mendelian randomization: use of genetic instrumental variables for assessing causal associations. Chapter 4: Collapsibility for IV analyses of binary outcomes. PhD thesis, University of Cambridge. Available at http://www.dspace.cam.ac.uk/handle/1810/242184. (Cited on page 59.)
26. Burgess, S. 2012b. Statistical issues in Mendelian randomization: use of genetic instrumental variables for assessing causal associations. Chapter 8: Meta-analysis of Mendelian randomization studies of C-reactive protein and coronary heart disease. PhD thesis, University of Cambridge. Available at http://www.dspace.cam.ac.uk/handle/1810/242184. (Cited on page 170.)
27. Burgess, S. 2014. Sample size andpowercalculationsin Mendelian randomization with asingle instrumental variable and abinary outcome. International Journal of Epidemiology, 43(3):922–929. (Cited on page 131.)
28. Burgess, S., Butterworth, A., and Thompson, S. 2013. Mendelian randomization analysiswith multiple genetic variantsusing summarizeddata. Genetic Epidemiology, 37(7):658–665. (Cited on pages 90 and 142.)
29. Burgess, S. and CCGC (CHD CRP Genetics Collaboration) 2013. Identifying the odds ratio estimated by a two-stage instrumental variable analysis with a logisticregressionmodel. Statistics in Medicine, 32(27):4726–4747. (Cited on page 59.)
30. Burgess, S., Daniel, R., Butterworth, A., Thompson, S., and EPIC-InterAct Consortium 2014a. Network Mendelian randomization: extending instrumental variable techniques. International Journal of Epidemiology, available online before print. (Cited on page 179.)
31. Burgess, S., Davies, N., Thompson, S., and EPIC-InterAct Consortium 2014b. Instrumental variable analysis with anon-linear exposure–outcome relationship. Epidemiology, available online before print. (Cited on pages 47, 176, and 177.)
32. Burgess, S., Granell, R., Palmer, T., Didelez, V., and Sterne, J. 2014c. Lack of identification in semi-parametric instrumental variable models with binary outcomes. American Journal of Epidemiology, 180(1):111–119. (Cited on pages 66, 68, and 109.)
33. Burgess, S., Howson, J., Surendran, P., Thompson, S., and EPIC-CVD Consortium 2014d. Mendelian randomization in the post-GWAS era: the perils ofcausalinference without biologicalknowledge. Submitted for publication. (Cited on page 182.)
34. Burgess, S., Scott, R., Timpson, N., Davey Smith, G., Thompson, S., and EPIC-InterAct Consortium 2014e. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. European Journal of Epidemiology, available online before print. (Cited on pages 142 and 183.)
35. Burgess, S., Seaman, S., Lawlor, D., Casas, J., and Thompson, S. 2011a. Missing data methods in Mendelian randomization studies with multiple instruments. American Journal of Epidemiology, 174(9):1069–1076. (Cited on page 134.)
36. Burgess, S. and Thompson, S. 2011. Bias in causal estimates from Mendelian randomization studies with weak instruments. Statistics in Medicine, 30(11):1312–1323. (Cited on pages 101, 108, 109, and 114.)
37. Burgess, S. and Thompson, S. 2012. Improvement of bias and coverage in instrumental variable analysis with weak instruments for continuous and binary outcomes. Statistics in Medicine, 31(15):1582–1600. (Cited on pages 60, 62, 73, and 108.)
38. Burgess, S. and Thompson, S. 2013. Use of allele scores as instrumental variables for Mendelian randomization. International Journal of Epidemiology, 42(4):1134–1144. (Cited on pages 125 and 126.)
39. Burgess, S. and Thompson, S. 2014. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. American Journal of Epidemiology, available online before print. (Cited on page 178.)
40. Burgess, S., Thompson, S., and CRP CHD Genetics Collaboration 2011b. Avoiding bias from weak instruments in Mendelian randomization studies. International Journal of Epidemiology, 40(3):755–764. (Cited on pages 68 and 116.)
41. Burgess, S., Thompson, S., and CRP CHD Genetics Collaboration 2012. Methods for meta-analysis of individual participant data from Mendelian randomizationstudies with binary outcomes. Statistical Methods in Medical Research, available online before print. (Cited on pages 157 and 161.)
42. Cai, B., Small, D., and Ten Have, T. 2011. Two-stage instrumental variable methods for estimating the causal odds ratio: Analysis of bias. Statistics in Medicine, 30(15):1809–1824. (Cited on page 60.)
43. Casas, J., Bautista, L., Smeeth, L., Sharma, P., and Hingorani, A. 2005. Homocysteine and stroke: evidence on a causal link from Mendelian randomisation. The Lancet, 365(9455):224–232. (Cited on page 11.)
44. CCGC (CRP CHD Genetics Collaboration) 2008. Collaborative pooled analysis of data on C-reactiveprotein gene variants and coronary disease: judging causality by Mendelian randomisation. European Journal of Epidemiology, 23(8):531–540. (Cited on pages 9, 117, 157, and 161.)
45. CCGC (CRPCHD Genetics Collaboration) 2011. Association between Creactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. British Medical Journal, 342:d548. (Cited on pages 88, 116, 159, and 162.)
46. Chaussé, P. 2010. Computing generalized method of moments and generalized empirical likelihood with R. Journal of Statistical Software, 34(11):1–35. (Cited on page 72.)
47. Chen, L., Davey Smith, G., Harbord, R., and Lewis, S. 2008. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Medicine, 5(3):e52. (Cited on page 11.)
48. Cheung, B., Lauder, I., Lau, C., and Kumana, C. 2004. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. British Journal of Clinical Pharmacology, 57(5):640–651. (Cited on page 91.)
49. Christenfeld, N., Sloan, R., Carroll, D., and Greenland, S. 2004. Risk factors, confounding, and the illusion of statistical control. Psychosomatic Medicine, 66(6):868–875. (Cited on page 16.)
50. Clarke, P., Palmer, T., and Windmeijer, F. 2011. Estimating structural mean modelswithmultiple instrumentalvariablesusingthegeneralisedmethod of moments. The Centre for Market and Public Organisation 11/266, Centre for Market and Public Organisation, University of Bristol, UK. (Cited on page 72.)
51. Clarke, P. and Windmeijer, F. 2010. Instrumental variable estimators for binary outcomes. The Centre for Market and Public Organisation 10/239, Centre for Market and Public Organisation, University of Bristol, UK. (Cited on pages 38, 63, 65, and 66.)
52. Clarke, R., Peden, J., Hopewell, J., et al. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New England Journal of Medicine, 361(26):2518–2528. (Cited on pages 11 and 81.)
53. Cohen, J., Boerwinkle, E., Mosley Jr, T., and Hobbs, H. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine, 354(12):1264–1272. (Cited on page 95.)
54. Collett, D. 2003. Modelling survival data in medical research. Chapman and Hall/CRC Press. (Cited on page 175.)
55. Collins, R., Armitage, J., Parish, S., Sleight, P., Peto, R. (Heart Protection Study Collaborative Group) 2002. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. The Lancet, 360(9326):23–33. (Cited on page 4.)
56. Cox, D. 1958. Planning of experiments. Section 2: Some key assumptions. Wiley. (Cited on page 41.)
57. Danesh, J. and Pepys, M. 2009. C-reactive protein and coronary disease: is there a causal link? Circulation, 120(21):2036–2039. (Cited on page 7.)
58. Darwin, C. 1871. The descent of man and selection in relation to sex. Murray, London. (Cited on page 5.)
59. Dastani, Z., Hivert, M.-F., Timpson, N., et al. 2012. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: A multiethnic meta-analysis of 45,891 individuals. PLoS Genetics, 8(3):e1002607. (Cited on page 142.)
60. Davey Smith, G. 2006. Randomised by (your) god: robust inference from an observational study design. Journal of Epidemiology and Community Health, 60(5):382–388. (Cited on page 88.)
61. Davey Smith, G. 2011. Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health. Genes & Nutrition, 6(1):27–43. (Cited on pages 17, 35, and 89.)
62. Davey Smith, G. and Ebrahim, S. 2003. ‘Mendelian randomization’: can geneticepidemiologycontributetounderstandingenvironmentaldeterminants of disease? International Journal of Epidemiology, 32(1):1–22. (Cited on pages 4, 5, and 20.)
63. Davey Smith, G. and Ebrahim, S. 2004. Mendelian randomization: prospects, potentials, and limitations. International Journal of Epidemiology, 33(1):30–42. (Cited on pages 23 and 123.)
64. Davey Smith, G., Lawlor, D., Harbord, R., Timpson, N., Day, I., and Ebrahim, S. 2007. Clustered environments and randomized genes: a fundamental distinction between conventionaland genetic epidemiology. PLoS Medicine, 4(12):e352. (Cited on page 18.)
65. Davidson, R. and MacKinnon, J. 1993. Estimation and inference in econometrics. Chapter 18: Simultaneous equation models. Oxford University Press. (Cited on page 61.)
66. Davidson, R. and MacKinnon, J. 2014. Confidence sets based on inverting Anderson–Rubin tests. The Econometrics Journal, 17(2):S39–S58. (Cited on page 54.)
67. Davies, N., von Hinke Kessler Scholder, S. Farbmacher, H. Burgess, S. Windmeijer, F., and Davey Smith, G. 2014. The many weak instrument problem and Mendelian randomization. Statistics in Medicine, available online before print. (Cited on pages 61, 108, and 126.)
68. Davignon, J. and Laaksonen, R. 1999. Low-density lipoprotein-independent effects of statins. Current Opinion in Lipidology, 10(6):543–559. (Cited on page 91.)
69. Dawid, A. 2000. Causal inference without counterfactuals. Journal of the American Statistical Association, 95(450):407–424. (Cited on page 26.)
70. Dawid, A. 2002. Influence diagrams for causal modelling and inference. International Statistical Review, 70(2):161–189. (Cited on page 37.)
71. Debat, V. and David, P. 2001. Mapping phenotypes: canalization, plasticity and developmental stability. Trends in Ecology & Evolution, 16(10):555– 561. (Cited on page 31.)
72. Dekkers, O., von Elm, E., Algra, A., Romijn, J., and Vandenbroucke, J. 2010. How to assess the external validity of therapeutic trials: a conceptual approach. International Journal of Epidemiology, 39(1):89–94. (Cited on page 93.)
73. Didelez, V., Meng, S., and Sheehan, N. 2010. Assumptions of IV methods for observational epidemiology. Statistical Science, 25(1):22–40. (Cited on pages 38, 48, and 51.)
74. Didelez, V. and Sheehan, N. 2007. Mendelian randomization as an instrumental variable approachto causal inference. Statistical Methods in Medical Research, 16(4):309–330. (Cited on pages 34, 37, 42, 43, and 51.)
75. Ding, E., Song, Y., Manson, J., et al. 2009a. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine, 361(12):1152–1163. (Cited on page 11.)
76. Ding, W., Lehrer, S., Rosenquist, J., and Audrain-McGovern, J. 2009b. The impact of poor health on academic performance: new evidence using genetic markers. Journal of Health Economics, 28(3):578–597. (Cited on page 11.)
77. Drukker, D. 2009. Generalized method of moments estimation in Stata 11. Technical report, Stata Corp. (Cited on page 71.)
78. Ducharme, G. and LePage, Y. 1986. Testing collapsibility in contingency tables. Journal of the Royal Statistical Society: Series B (Methodological), 48(2):197–205. (Cited on page 58.)
79. Dudbridge, F. 2013. Power and predictive accuracy of polygenic risk scores. PLoS Genetics, 9(3):e1003348. (Cited on page 182.)
80. Dunn, G., Maracy, M., and Tomenson, B. 2005. Estimating treatment effects from randomized clinical trials with noncompliance and loss to follow-up: the role of instrumental variable methods. Statistical Methods in Medical Research, 14(4):369–395. (Cited on page 65.)
81. Ebrahim, S. and Davey Smith, G. 2008. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Human Genetics, 123(1):15–33. (Cited on pages 11, 35, and 56.)
82. Efron, B. and Tibshirani, R. 1993. An introduction to the bootstrap. Chapman & Hall/CRC Press. (Cited on page 54.)
83. Ehret, G., Munroe, P., Rice, K., et al. (The International Consortium for Blood Pressure Genome-Wide Association Studies) 2011. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 478:103–109. (Cited on page 93.)
84. Elliott, P., Chambers, J., Zhang, W., et al. 2009. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. Journal of the American Medical Association, 302(1):37–48. (Cited on page 88.)
85. Emsley, R., Dunn, G., and White, I. 2010. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Statistical Methods in Medical Research,19(3):237–270.(Citedonpage180.)
86. Evans, D., Brion, M.-J., Paternoster, L., et al. 2013. Mining the human phenomeusing all elicscores that index biological intermediates. PLoS Genetics, 9(10):e1003919. (Cited on page 182.)
87. Farnier, M. 2013. PCSK9 inhibitors. Current Opinion in Lipidology, 24(3):251–258. (Cited on page 95.)
88. Fieller, E. 1954. Some problems in interval estimation. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 16(2):175–185.(Cited on page 52.)
89. Fischer-Lapp, K. and Goetghebeur, E. 1999. Practical properties of some structural mean analyses of the effect of compliance in randomized trials. Controlled Clinical Trials, 20(6):531–546. (Cited on page 65.)
90. Fisher, R. 1918. The correlation between relatives on the supposition of Mendelian inheritance. Transactions of the Royal Society of Edinburgh, 52(2):399–433. (Cited on page 5.)
91. Foster, E. 1997. Instrumental variables for logistic regression: an illustration. Social Science Research, 26(4):487–504. (Cited on pages 58 and 64.)
92. Fox, J. 2006. Teacher’s Corner: Structural Equation Modeling with the sem Package in R. Structural Equation Modeling: A Multidisciplinary Journal, 13(3):465–486. (Cited on page 72.)
93. Freeman G., Cowling B., Schooling M. 2013. Power and sample size calculations for Mendelian randomization studies. International Journal of Epidemiology, 42(4):1157–1163. (Cited on pages 127 and 131.)
94. Fried, L., Borhani, N., Enright, P., et al. 1991. The Cardiovascular Health Study: Design and rationale. Annals of Epidemiology, 1(3):263–276. (Cited on page 164.)
95. Frost, C. and Thompson, S. 2000. Correcting for regression dilution bias: comparison of methods for a single predictor variable. Journal of the Royal Statistical Society: Series A (Statistics in Society), 163(2):173–189. (Cited on page 19.)
96. Geiger, D., Verma, T., and Pearl, J. 1990. Identifying independence in Bayesian networks. Networks, 20(5):507–534. (Cited on page 27.)
97. Gidding, S., Daniels, S., Kavey, R., and Expert Panelon Cardiovascular Health and Risk Reductionin Youth 2012. Developing the 2011 integrated pediatric guidelines for cardio vascularrisk reduction. Pediatrics, 129(5):e1311–e1319. (Cited on page 84.)
98. Glymour, M., TchetgenTchetgen, E., andRobins, J.2012.CredibleMendelian randomization studies: approaches for evaluating the instrumental variable assumptions. American Journal of Epidemiology, 175(4):332–339. (Cited on pages 34, 35, 68, and 95.)
99. Grassi, M., Assanelli, D., and Pezzini, A. 2007. Direct, reverse or reciprocal causation in the relation between homocysteine and ischemic heart disease. Thrombosis Research, 120(1):61–69. (Cited on page 179.)
100. Greenland, S. 1987. Interpretation and choice of effect measures in epidemiologic analyses. American Journal of Epidemiology, 125(5):761–768. (Cited on page 42.)
101. Greenland, S. 2000a. An introduction to instrumental variables for epidemiologists. International Journal of Epidemiology, 29(4):722–729. (Cited on page 14.)
102. Greenland, S. 2000b. Causal analysis in the health sciences. Journal of the American Statistical Association, 95(449):286–289. (Cited on page 26.)
103. Greenland, S., Lanes, S., and Jara, M. 2008. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clinical Trials, 5(1):5–13. (Cited on page 65.)
104. Greenland, S. and Robins, J. 1986. Identifiability, exchangeability, and epidemiological confounding. International Journal of Epidemiology, 15(3):413–419. (Cited on pages 14, 28, and 30.)
105. Greenland, S., Robins, J., and Pearl, J. 1999. Confounding and collapsibility in causal inference. Statistical Science, 14(1):29–46. (Cited on page 58.)
106. Hahn, J., Hausman, J., and Kuersteiner, G. 2004. Estimation with weak instruments: accuracy of higher-order bias and MSE approximations. Econometrics Journal, 7(1):272–306. (Cited on page 61.)
107. Hall, A., Rudebusch, G., and Wilcox, D. 1996. Judging instrument relevance in instrumental variablesestimation. International Economic Review, 37(2):283–298. (Cited on pages 111 and 114.)
108. Hansen, L. 1982. Large sample properties of generalized method of moments estimators. Econometrica: Journal of the Econometric Society, 50(4):1029–1054. (Cited on page 64.)
109. Hansson, G. 2005. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16):1685–1695. (Cited on page 116.)
110. Hardin, J., Schmiediche, H., and Carroll, R. 2003. Instrumental variables, bootstrapping, and generalized linear models. Stata Journal, 3(4):351–360. (Cited on pages 71 and 72.)
111. Hayashi, F. 2000. Econometrics. Princeton University Press. (Cited on page 61.)
112. Hennekens, C., Buring, J., Manson, J., et al. 1996. Lack of effect of longterm supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New England Journal of Medicine, 334(18):1145–1149. (Cited on page 4.)
113. Hernán, M. and Robins, J. 2006. Instruments for causal inference: an epidemiologist’s dream? Epidemiology, 17(4):360–372. (Cited on pages 17, 32, and 39.)
114. Hernán, M. and Taubman, S. 2008. Does obesity shorten life? The importance of well-defined inter ventionsto answer causalquestions. International Journal of Obesity, 32:S8–S14. (Cited on page 136.)
115. Higgins, J., Thompson, S., Deeks, J., and Altman, D. 2003. Measuring inconsistency in meta-analyses. British Medical Journal, 327(7414):557–560. (Cited on page 168.)
116. Hill, A. B. 1965. The environment and disease: association or causation? Proceedings of the Royal Society of Medicine, 58(5):295–300. (Cited on page 35.)
117. Hingorani, A. and Humphries, S. 2005. Nature’s randomised trials. The Lancet, 366(9501):1906–1908. (Cited on page 69.)
118. Holland, P. 1986. Statistics and causal inference. Journal of the American Statistical Association, 81(396):945–960. (Cited on pages 25 and 26.)
119. Hooper, L., Ness, A., and Davey Smith, G. 2001. Antioxidant strategyfor cardiovascular diseases. The Lancet, 357(9269):1705–1706. (Cited on page 4.)
120. Horowitz, J. L. 2011. Applied nonparametric instrumental variables estimation. Econometrica, 79(2):347–394. (Cited on pages 42 and 176.)
121. Imbens, G. and Rosenbaum, P. 2005. Robust, accurate confidence intervals with a weak instrument: quarter of birth and education. Journal of the Royal Statistical Society: Series A (Statistics in Society), 168(1):109–126. (Cited on pages 54 and 108.)
122. Inoue, A. and Solon, G. 2010. Two-sample instrumental variables estimators. The Review of Economics and Statistics, 92(3):557–561. (Cited onpages137 and 155.)
123. Irons, D., McGue, M., Iacono, W., and Oetting, W. 2007. Mendelian randomization: A novel test of the gateway hypothesis and models of gene– environmentinterplay. Development and Psychopathology, 19(4):1181–1195. (Cited on page 11.)
124. Jansen, R. and Nap, J.-P. 2001. Genetical genomics: the added value from segregation. Trends in Genetics, 17(7):388–391. (Cited on page 180.)
125. Johnson, T. 2011. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Technical report, Queen Mary University of London. (Cited on page 142.)
126. Johnston, K., Gustafson, P., Levy, A., and Grootendorst, P. 2008. Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research. Statistics in Medicine, 27(9):1539–1556. (Cited on pages 64 and 65.)
127. Jones, E., Thompson, J., Didelez, V., and Sheehan, N. 2012. On the choice of parameterisation and priors for the Bayesian analyses of Mendelian randomisation studies. Statistics in Medicine, 31(14):1483–1501. (Cited on page 62.)
128. Kamstrup, P., Tybjaerg-Hansen, A., Steffensen, R., and Nordestgaard, B. 2009. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. Journal of the American Medical Association, 301(22):2331– 2339. (Cited on pages 11 and 80.)
129. Kaptoge, S., Di Angelantonio, E., Lowe, G. et al. (Emerging Risk Factors Collaboration) 2010. C-reactive protein concentration and risk of coronary heartdisease, stroke, and mortality: anindividual participantmeta-analysis. The Lancet, 375(9709):132–140. (Cited on pages 7 and 116.)
130. Keavney, B. 2011. C reactive protein and the risk of cardiovascular disease. British Medical Journal, 342:d144. (Cited on page 171.)
131. Keavney, B., Danesh, J., Parish, S., et al. 2006. Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. International Journal of Epidemiology, 35(4):935–943. (Cited on page 75.)
132. Khaw, K., Bingham, S., Welch, A., et al. 2001. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. The Lancet, 357(9257):657–663. (Cited on page 4.)
133. Kinal, T. 1980. The existence of moments of k-classestimators. Econometrica, 48(1):241–249. (Cited on page 57.)
134. Kivimäki, M., Lawlor, D., Davey Smith, G., et al. 2008. Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS ONE, 3(8):e3013. (Cited on page 11.)
135. Kivimäki, M., Lawlor, D., Eklund, C., et al. 2007. Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(4):978–979. (Cited on page 11.)
136. Kleiber, C. and Zeileis, A. 2014. AER: Applied Econometrics with R. R package version 1.2-2. (Cited on page 72.)
137. Kleibergen, F. and Zivot, E. 2003. Bayesian and classical approaches to instrumental variable regression. Journal of Econometrics, 114(1):29–72. (Cited on page 62.)
138. Klein, R., Zeiss, C., Chew, E., et al. 2005. Complement factor Hpolymorphism in age-relatedmacular degeneration. Science, 308(5720):385–389. (Cited on page 181.)
139. Law, M., Morris, J., and Wald, N. 2009. Use of blood pressure lowering drugs in the prevention ofcardiovasculardisease: meta-analysisof147randomised trials in the context of expectations from prospective epidemiological studies. British Medical Journal, 338:b1665. (Cited on page 93.)
140. Law, M., Wald, N., and Rudnicka, A. 2003. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. British Medical Journal, 326(7404):1423. (Cited on page 91.)
141. Lawlor, D., Harbord, R., Sterne, J., Timpson, N., and Davey Smith, G. 2008. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in Medicine, 27(8):1133–1163. (Cited on pages 20, 21, 52, and 67.)
142. Le Marchand, L., Derby, K., Murphy, S., et al. 2008. Smokers with the CHRNA lung cancer–associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Research, 68(22):9137–9140. (Cited on page 179.)
143. Lewis, S. and Davey Smith, G. 2005. Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiology Biomarkers & Prevention, 14(8):1967–1971. (Cited on page 23.)
144. Little, R. and Rubin, D. 2002. Statistical analysis with missing data (2nd edition). Wiley. (Cited on page 134.)
145. Lunn, D., Whittaker, J., and Best, N. 2006. A Bayesian tool kit forgeneticassociation studies. Genetic Epidemiology, 30(3):231–247. (Cited on page 135.)
146. Maldonado, G. and Greenland, S. 2002. Estimating causal effects. International Journal of Epidemiology, 31(2):422–429. (Cited on page 26.)
147. Manolio, T. 2010. Genomewide association studies and assessment of the risk of disease. New England Journal of Medicine, 363(2):166–176. (Cited on page 181.)
148. Martens, E., Pestman, W., de Boer, A., Belitser, S., and Klungel, O. 2006. Instrumental variables: application and limitations. Epidemiology, 17(3):260– 267. (Cited on pages 16 and 93.)
149. McPherson, J., et al. (The International Human Genome Mapping Consortium) 2001. A physical map of the human genome. Nature, 409(6822):934–941. (Cited on page 5.)
150. Mendel, G. 1866. VersucheüberPflanzen-hybriden. Verhandlungen des naturforschenden Vereines in Brünn [Proceedings of the Natural History Society of Brünn], 4:3–47. (Cited on page 5.)
151. Mikusheva, A. 2010. Robust confidence sets in the presence of weak instruments. Journal of Econometrics, 157(2):236–247. (Cited on pages 54 and 108.)
152. Mikusheva, A. and Poi, B. 2006. Tests and confidence sets with correct size when instruments are potentially weak. Stata Journal, 6(3):335–347. (Cited on pages 54 and 108.)
153. Minelli, C., Thompson, J., Tobin, M., and Abrams, K. 2004. An integrated approachtothemeta-analysisofgeneticassociationstudiesusingMendelian randomization. American Journal of Epidemiology, 160(5):445–452. (Cited on pages 51, 52, and 140.)
154. Mogstad, M. and Wiswall, M. 2010. Linearity in instrumental variables estimation: Problems and solutions. Technical report, Forschungsinstitut zur Zukunft der Arbeit. Bonn, Germany. (Cited on pages 42 and 176.)
155. Moreira, M. 2003. A conditional likelihood ratio test for structural models. Econometrica, 71(4):1027–1048. (Cited on pages 54 and 108.)
156. Moreira, M., Porter, J., and Suarez, G. 2009. Bootstrap validity for the score test when instruments may be weak. Journal of Econometrics, 149(1):52–64. (Cited on page 54.)
157. Morris, A., Voight, B., Teslovich, T., et al. 2012. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nature Genetics, 44(9):981–990. (Cited on page 146.)
158. Mumby, H., Elks, C., Li, S., et al. 2011. Mendelian randomisation study of childhood BMI and early menarche. Journal of Obesity, available online before print. (Cited on page 11.)
159. Nagelkerke, N., Fidler, V., Bernsen, R., and Borgdorff, M. 2000. Estimating treatment effects in randomized clinical trials in the presence of noncompliance. Statistics in Medicine, 19(14):1849–1864. (Cited on page 60.)
160. Nelson, C. and Startz, R. 1990. The distribution of the instrumental variables estimator and its t-ratio when the instrument is a poor one. Journal of Business, 63(1):125–140. (Cited on pages 99 and 126.)
161. Nitsch, D., Molokhia, M., Smeeth, L., DeStavola, B., Whittaker, J., and Leon, D. 2006. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. American Journal of Epidemiology, 163(5):397–403. (Cited on page 16.)
162. Norton, E. and Han, E. 2008. Genetic information, obesity, and labor market outcomes. Health Economics, 17(9):1089–1104. (Cited on page 11.)
163. Ogbuanu, I., Zhang, H., and Karmaus, W. 2009. Can we apply the Mendelian randomization methodology without considering epigenetic effects? Emerging Themes in Epidemiology, 6(1):3. (Cited on page 32.)
164. Palmer, T., Lawlor, D., Harbord, R., et al. 2011a. Using multiple genetic variants as instrumental variables for modifiable risk factors. Statistical Methods in Medical Research, 21(3):223–242. (Cited on pages 114 and 123.)
165. Palmer, T., Sterne, J., Harbord, R., et al. 2011b. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. American Journal of Epidemiology, 173(12):1392–1403. (Cited on pages 64 and 71.)
166. Palmer, T., Thompson, J., Tobin, M., Sheehan, N., and Burton, P. 2008. Adjusting for bias and unmeasured confounding in Mendelian randomization studies with binary responses. International Journal of Epidemiology, 37(5):1161–1168. (Cited on pages 37 and 60.)
167. Pauling, L., Itano, H., Singer, S., and Wells, I. 1949. Sickle cell anemia, a molecular disease. Science, 110(2865):543–548. (Cited on page 5.)
168. Pearl, J. 2000a. Causality: models, reasoning, and inference. Cambridge University Press. (Cited on page 25.)
169. Pearl, J. 2000b. Causality: models, reasoning, and inference. Chapter 3, Section 3.1: The back-door criterion. Cambridge University Press. (Cited on page 28.)
170. Pearl, J. 2001. Direct and indirect effects. In Proceedings of the Seventeenth Conference on Uncertainty in Artificial Intelligence, pages 411–420. (Cited on page 180.)
171. Pearl, J. 2010. An introduction to causal inference. The International Journal of Biostatistics, 6(2):1–60. (Cited on page 26.)
172. Peto, R., Doll, R., Buckley, J., and Sporn, M. 1981. Can dietary beta-carotene materially reduce human cancer rates? Nature, 290:201–208. (Cited on page 4.)
173. Pierce, B., Ahsan, H., and VanderWeele, T. 2011. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. International Journal of Epidemiology, 40(3):740–752. (Cited on pages 114 and 131.)
174. Pierce, B. and Burgess, S. 2013. Efficient design for Mendelian randomization studies: subsample and two-sample instrumental variable estimators. American Journal of Epidemiology, 178(7):1177–1184. (Cited on page 137.)
175. Pierce, B. and Vander Weele, T. 2012. The effect of non-differential measurement error on bias, precision and power in Mendelian randomization studies. International Journal of Epidemiology, 41(5):1383–1393. (Cited on page 19.)
176. Plenge, R., Scolnick, E., and Altshuler, D. 2013. Validating the rapeutictar gets through human genetics. Nature Reviews Drug Discovery, 12(8):581–594. (Cited on page 94.)
177. R Development Core Team 2011. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. (Cited on page 69.)
178. Raal, F., Giugliano, R., Sabatine, M., et al. 2014. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab(AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. Journal of the American College of Cardiology, 63(13):1278–1288. (Cited on page 95.)
179. Rasbash, J., Steele, F., Browne, W., and Goldstein, H. 2009. A user’s guide to MLwiN, v2. 10. Centre for Multilevel Modelling, University of Bristol. (Cited on page 141.)
180. Relton, C. and Davey Smith, G. 2010. Epigenetic epidemiology of common complex disease: Prospects for prediction, prevention, and treatment. PLoS Medicine, 7(10):e1000356. (Cited on page 180.)
181. Relton, C. and Davey Smith, G. 2012a. Is epidemiology ready for epigenetics? International Journal of Epidemiology, 41(1):5–9. (Cited on page 180.)
182. Relton, C. and Davey Smith, G. 2012b. Two-step epigenetic Mendelian randomization: astrategy for establishing the causal role of epigenetic processes in pathways to disease. International Journal of Epidemiology, 41(1):161–176. (Cited on page 181.)
183. Riley, R., Abrams, K., Sutton, A., Lambert, P., and Thompson, J. 2007. Bivariate random-effects meta-analysis and the estimation of between-study correlation. BMC Medical Research Methodology, 7(1):3. (Cited on page 141.)
184. Roberts, L., Davenport, R., Pennisi, E., and Marshall, E. 2001. A history of the Human Genome Project. Science, 291(5507):1195. (Cited on page 5.)
185. Robins, J. 1986. A new approach to causal inference in mortality studies with a sustained exposure period–application to control of the healthy worker survivor effect. Mathematical Modelling, 7(9-12):1393–1512. (Cited on page 65.)
186. Robins, J. 1992. Semiparametric estimation of an accelerated failure time model with time-dependent covariates. Biometrika, 79(2):311–334. (Cited on page 176.)
187. Robins, J. 1994. Correcting for non-compliance in randomized trials using structural nested mean models. Communications in Statistics – Theory and Methods, 23(8):2379–2412. (Cited on page 65.)
188. Robins, J. 1999. Statistical models in epidemiology: the environment and clinical trials, chapter Marginal structural models versus structural nested models as tools for causal inference, pages 95–134. Springer. (Cited on page 66.)
189. Robinson, J., Nedergaard, B., Rogers, W., et al. 2014. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDLC lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Journal of the American Medical Association, 311(18):1870–1882. (Cited on page 95.)
190. Rossouw, J., et al. (Writing Group for the Women’s Health Initiative Investigators) 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association, 288(3):321–333. (Cited on page 4.)
191. Rothwell, P. 2010. Commentary: External validity of results of randomized trials: disentangling a complex concept. International Journal of Epidemiology, 39(1):94–96. (Cited on page 87.)
192. Rubin, D. 1974. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology, 66(5):688–701. (Cited on page 30.)
193. Sargan, J. 1958. The estimation of economic relationships using instrumental variables. Econometrica, 26(3):393–415. (Cited on page 68.)
194. Sarwar, N., Butterworth, A., Freitag, D., et al. (IL6R Genetics Consortium and Emerging Risk Factors Collaboration) 2012. Interleukin-6 receptor pathway sincoronary heart disease: a collaborative meta-analysis of 82 studies. Lancet, 379(9822):1205–1213. (Cited on page 20.)
195. SAS (SAS Institute and SAS Publishing Staff) 2004. SAS/STAT 9.1 User’s Guide. SAS Institute Inc, Cary, NC. (Cited on page 69.)
196. Schatzkin, A., Abnet, C., Cross, A., et al. 2009. Mendelian randomization: how it can – and cannot – help confirm causal relations between nutrition and cancer. Cancer Prevention Research, 2(2):104–113. (Cited on pages 24 and 89.)
197. Scheet, P. and Stephens, M. 2006. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. American Journal of Human Genetics, 78(4):629–644. (Cited on page 134.)
198. Schunkert, H., König, I., Kathiresan, S., et al. 2011. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 43(4):333–338. (Cited on page 146.)
199. Sheehan, N., Didelez, V., Burton, P., and Tobin, M. 2008. Mendelianrandomisation and causal inference in observational epidemiology. PLoS Medicine, 5(8):e177. (Cited on page 20.)
200. Shendure, J. and Ji, H. 2008. Next-generation DNA sequencing. Nature Biotechnology, 26(10):1135–1145. (Cited on page 5.)
201. Small, D. 2014. ivpack: Instrumental Variable Estimation. R package version 1.1. (Cited on pages 54 and 72.)
202. Small, D. and Rosenbaum, P. 2008. War and wages: the strength of instrumental variables and their sensitivity to unobvserved biases. Journal of the American Statistical Association, 103(483):924–933. (Cited on page 121.)
203. Speliotes, E., Willer, C., Berndt, S., et al. 2010. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 42(11):937–948. (Cited on page 176.)
204. Spiegelhalter, D., Best, N., Carlin, B., and Linde, A. 2002. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 64(4):583–639. (Cited on page 152.)
205. Spiegelhalter, D., Thomas, A., Best, N., and Lunn, D. 2003. WinBUGSversion 1.4usermanual. Technical report, MRC Biostatistics Unit, Cambridge, UK. (Cited on pages 62, 69, and 141.)
206. Spirtes, P., Glymour, C., and Scheines, R. 2000. Causation, prediction, and search. MIT Press. (Cited on page 39.)
207. Staiger, D. and Stock, J. 1997. Instrumental variables regression with weak instruments. Econometrica, 65(3):557–586. (Cited on pages 67 and 106.)
208. StataCorp 2009. Stata Statistical Software: Release 11. College Station, TX. (Cited on page 69.)
209. Sterne, J. and Davey Smith, G. 2001. Sifting the evidence – What’s wrong with significance tests? British Medical Journal, 322:226–231. (Cited on page 96.)
210. Stock, J., Wright, J., and Yogo, M. 2002. A survey of weak instruments and weak identification in generalized method of moments. Journal of Business and Economic Statistics, 20(4):518–529. (Cited on page 67.)
211. Stock, J. and Yogo, M. 2002. Testing for weak instruments in linear IV regression. SSRN eLibrary, 11:T0284. (Cited on pages 70, 108, and 118.)
212. Stukel, T., Fisher, E., Wennberg, D., Alter, D., Gottlieb, D., and Vermeulen, M. 2007. Analysis of observational studies in the presence of treatment selection bias. Journal of the American Medical Association, 297(3):278–285. (Cited on page 59.)
213. Sussman, J. and Hayward, R. 2010. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. British Medical Journal, 340:c2073. (Cited on page 14.)
214. Sutton, A., Kendrick, D., and Coupland, C. 2008. Meta-analysisof individualand aggregate-level data. Statistics in Medicine, 27(5):651–669. (Cited on page 150.)
215. Swanson, S. and Hernán, M. 2013. Commentary: how to report instrumental variable analyses (suggestions welcome). Epidemiology, 24(3):370–374. (Cited on page 42.)
216. Swerdlow, D., Holmes, M., Kuchenbaecker, K., et al. (The Inter leukin-6 Receptor Mendelian Randomisation Analysis Consortium) 2012. The interleukin6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet, 379(9822):1214–1224. (Cited on pages 19, 36, and 183.)
217. Taubes, G. and Mann, C. 1995. Epidemiology faces its limits. Science, 269(5221):164–169. (Cited on page 4.)
218. Taylor, A., Davies, N., Ware, J., VanderWeele, T., Davey Smith, G., and Munafò, M. 2014. Mendelian randomization in health research: Using appropriate genetic variants and avoiding biased estimates. Economics & Human Biology, 13:99–106. (Cited on page 125.)
219. Taylor, F., Ward, K., Moore, T., et al. 2013. Statins forth eprimary prevention of cardiovasculardisease. Cochrane Database of Systematic Reviews, 2013:1. (Cited on page 91.)
220. Terza, J., Basu, A., and Rathouz, P. 2008. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. Journal of Health Economics, 27(3):531–543. (Cited on page 60.)
221. Thomas, D. and Conti, D. 2004. Commentary: the concept of ‘Mendelian Randomization’. International Journal of Epidemiology, 33(1):21–25. (Cited on page 14.)
222. Thomas, D., Lawlor, D., and Thompson, J. 2007. Re: Estimation of bias in nongenetic observational studies using “Mendelian triangulation” by Bautista et al. Annals of Epidemiology, 17(7):511–513. (Cited on pages 52 and 69.)
223. Thompson, J., Minelli, C., Abrams, K., Tobin, M., and Riley, R. 2005. Metaanalysis of genetic studies using Mendelian randomization – a multivariate approach. Statistics in Medicine, 24(14):2241–2254. (Cited on pages 11, 90, 116, 141, 144, 145, and 154.)
224. Timpson, N., Harbord, R., Davey Smith, G., Zacho, J., Tybjærg-Hansen, A., and Nordestgaard, B. 2009. Does greater adiposity increase blood pressure and hypertension risk? Mendelian randomization using the FTO/MC4R genotype. Hypertension, 54(1):84–90. (Cited on page 77.)
225. Timpson, N., Lawlor, D., Harbord, R., et al. 2005. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. The Lancet, 366(9501):1954–1959. (Cited on page 11.)
226. Timpson, N., Nordestgaard, B., Harbord, R., et al. 2011. C-reactive protein levels and body massindex: elucidating direction nofcausation through reciprocal Mendelian randomization. International Journal of Obesity, 35:300–308. (Cited on page 179.)
227. Tobin, M., Minelli, C., Burton, P., and Thompson, J. 2004. Commentary: Development of Mendelian randomization: from hypothesis test to ‘Mendelian deconfounding’. International Journal of Epidemiology, 33(1):26–29. (Cited on pages 16 and 39.)
228. Trompet, S., Jukema, J., Katan, M., et al. 2009. Apolipoprotein E genotype, plasmacholesterol, and cancer: a Mendelian randomization study. American Journal of Epidemiology, 170(11):1415–1421. (Cited on page 11.)
229. Vander Weele, T. 2009. Concerning the consistency assumption in causal inference. Epidemiology, 20(6):880–883. (Cited on page 50.)
230. Vander Weele, T., Asomaning, K., Tchetgen Tchetgen, E., et al. 2012. Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. American Journal of Epidemiology, 175(10):1013–1020. (Cited on page 179.)
231. Vander Weele, T., Tchetgen Tchetgen, E., Cornelis, M., and Kraft, P. 2014. Methodological challenges in Mendelian randomization. Epidemiology, 25(3):427–435. (Cited on page 96.)
232. Vander Weele, T. and Vansteelandt, S. 2009. Conceptual issues concerning mediation, interventions and composition. Statistics and its Interface, 2(4):457–468. (Cited on page 180.)
233. Vansteelandt, S., Bowden, J., Babanezhad, M., and Goetghebeur, E. 2011. On instrumental variables estimation of causal odds ratios. Statistical Science, 26(3):403–422. (Cited on pages 59 and 66.)
234. Vansteelandt, S. and Goetghebeur, E. 2003. Causal inference with generalized structural mean models. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 65(4):817–835. (Cited on page 66.)
235. Voight, B., Peloso, G., Orho-Melander, M., et al. 2012. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet, 380(9841):572–580. (Cited on pages 11, 82, and 177.)
236. Hinke Kessler Scholder, S., Davey Smith, G., Lawlor, D., Propper, C., and Windmeijer, F. 2010. Genetic markers as instrumental variables: An application to child fat mass and academic achievement. The Centre for Market and Public Organisation 10/229, University of Bristol, UK. (Cited on page 11.)
237. Wald, A. 1940. The fitting of straight lines if both variables are subject to error. Annals of Mathematical Statistics, 11(3):284–300. (Cited onpage45.)
238. Wan, E., Qiu, W., Baccarelli, A., et al. 2012. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Human Molecular Genetics, 21(13):3073–3082. (Cited on page 180.)
239. Wardle, J., Carnell, S., Haworth, C., Farooqi, I., O’Rahilly, S., and Plomin, R. 2008. Obesity associated genetic variation in FTO is associated with diminished satiety. Journal of Clinical Endocrinology & Metabolism, 93(9):3640– 3643. (Cited on pages 31, 78, and 89.)
240. Waterworth, D., Ricketts, S., Song, K., et al. 2010. Geneticvariantsinfluencing circulating lipid levels and risk of coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(11):2264–2276. (Cited on page 90.)
241. Watson, J. and Crick, F. 1953. Molecular structure of nucleicacids: a structure for deoxyribose nucleic acid. Nature, 171(4356):737–738. (Cited on page 5.)
242. Wehby, G., Ohsfeldt, R., and Murray, J. 2008. “Mendelian randomization” equals instrumental variable analysis with genetic instruments. Statistics in Medicine, 27(15):2745–2749. (Cited on pages 14 and 68.)
243. Welsh, P., Polisecki, E., Robertson, M., et al. 2010. Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. Journal of Clinical Endocrinology & Metabolism, 95(1):93–99. (Cited on page 179.)
244. Wooldridge, J. 2009. Introductory econometrics: A modern approach. Chapter 5: Multiple regression analysis – OLS asymptotics. South-Western, Nashville, TN. (Cited on pages 56, 67, and 127.)
245. Wright, P. 1928. The tariff on animal and vegetable oils. Appendix B. Macmillan, New York. (Cited on page 10.)
246. Yang, J., Lee, S., Goddard, M., and Visscher, P. 2011. GCTA: a tool for genome-wide complex trait analysis. The American Journal of Human Genetics, 88(1):76–82. (Cited on page 182.)
247. Youngman, L., Keavney, B., Palmer, A., et al. 2000. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of my ocardialinfarction and in 6002 controls: test of causality by ‘Mendelianrandomization’. Circulation, 102(Suppl II):31–32. (Cited on page 9.)
248. Zacho, J., Tybjaerg-Hansen, A., Jensen, J., Grande, P., Sillesen, H., and Nordestgaard, B. 2008. Geneticall yelevated C-reactiveprotein and ischemic vascular disease. New England Journal of Medicine, 359(18):1897–1908. (Cited on page 100.)
249. Zohoori, N. and Savitz, D. 1997. Econometric approaches to epidemiologic data: Relating endogeneity and unobserved heterogeneity to confounding. Annals of Epidemiology, 7(4):251–257. (Cited on pages 56 and 110.)